Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

First outbreak with chimeric swine enteric coronavirus (SeCoV) on pig farms in Slovakia - lessons to learn.

Mandelik R, Sarvas M, Jackova A, Salamunova S, Novotny J, Vilcek S.

Acta Vet Hung. 2018 Sep;66(3):488-492. doi: 10.1556/004.2018.043.

PMID:
30264613
2.

Chlamydia pneumoniae entry into epithelial cells by clathrin-independent endocytosis.

Korhonen JT, Puolakkainen M, Haveri A, Tammiruusu A, Sarvas M, Lahesmaa R.

Microb Pathog. 2012 Mar;52(3):157-64. doi: 10.1016/j.micpath.2011.12.002. Epub 2011 Dec 21.

PMID:
22203235
3.

The density of negative charge in the cell wall influences two-component signal transduction in Bacillus subtilis.

Hyyryläinen HL, Pietiäinen M, Lundén T, Ekman A, Gardemeister M, Murtomäki-Repo S, Antelmann H, Hecker M, Valmu L, Sarvas M, Kontinen VP.

Microbiology. 2007 Jul;153(Pt 7):2126-36.

PMID:
17600057
4.

Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model.

Tammiruusu A, Penttilä T, Lahesmaa R, Sarvas M, Puolakkainen M, Vuola JM.

Vaccine. 2007 Jan 4;25(2):283-90. Epub 2006 Aug 11.

PMID:
16949182
5.

Systemic and mucosal antibody response in experimental Chlamydia pneumoniae infection of mice.

Penttilä T, Wahlström E, Vuola JM, Sarvas M, Puolakkainen M.

Comp Med. 2006 Aug;56(4):272-8.

PMID:
16941954
6.

NMR solution structure and characterization of substrate binding site of the PPIase domain of PrsA protein from Bacillus subtilis.

Tossavainen H, Permi P, Purhonen SL, Sarvas M, Kilpeläinen I, Seppala R.

FEBS Lett. 2006 Mar 20;580(7):1822-6. Epub 2006 Feb 24.

7.

Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice.

Tammiruusu A, Haveri A, Pascolo S, Lahesmaa R, Stevanovic S, Rammensee HG, Sarvas M, Puolakkainen M, Vuola JM.

Scand J Immunol. 2005 Aug;62(2):131-9.

8.
9.

Cationic antimicrobial peptides elicit a complex stress response in Bacillus subtilis that involves ECF-type sigma factors and two-component signal transduction systems.

Pietiäinen M, Gardemeister M, Mecklin M, Leskelä S, Sarvas M, Kontinen VP.

Microbiology. 2005 May;151(Pt 5):1577-92.

PMID:
15870467
10.

Transcriptome analysis of the secretion stress response of Bacillus subtilis.

Hyyryläinen HL, Sarvas M, Kontinen VP.

Appl Microbiol Biotechnol. 2005 May;67(3):389-96. Epub 2005 Jan 27.

PMID:
15856219
11.

Post-translocational folding of secretory proteins in Gram-positive bacteria.

Sarvas M, Harwood CR, Bron S, van Dijl JM.

Biochim Biophys Acta. 2004 Nov 11;1694(1-3):311-27. Review.

12.

DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model.

Penttilä T, Tammiruusu A, Liljeström P, Sarvas M, Mäkelä PH, Vuola JM, Puolakkainen M.

Vaccine. 2004 Sep 3;22(25-26):3386-94.

PMID:
15308363
13.

Structure-function analysis of PrsA reveals roles for the parvulin-like and flanking N- and C-terminal domains in protein folding and secretion in Bacillus subtilis.

Vitikainen M, Lappalainen I, Seppala R, Antelmann H, Boer H, Taira S, Savilahti H, Hecker M, Vihinen M, Sarvas M, Kontinen VP.

J Biol Chem. 2004 Apr 30;279(18):19302-14. Epub 2004 Feb 19.

14.
15.

Probing the ability of the coat and vertex protein of the membrane-containing bacteriophage PRD1 to display a meningococcal epitope.

Huiskonen JT, Laakkonen L, Toropainen M, Sarvas M, Bamford DH, Bamford JK.

Virology. 2003 Jun 5;310(2):267-79.

16.

Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model.

Airaksinen U, Penttilä T, Wahlström E, Vuola JM, Puolakkainen M, Sarvas M.

Clin Diagn Lab Immunol. 2003 May;10(3):367-75. Erratum in: Clin Diagn Lab Immunol. 2004 Mar;11(2):436.

17.

Essential Bacillus subtilis genes.

Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Chapuis J, Christiansen LC, Danchin A, Débarbouille M, Dervyn E, Deuerling E, Devine K, Devine SK, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C, Fukushima T, Haga K, Harwood CR, Hecker M, Hosoya D, Hullo MF, Kakeshita H, Karamata D, Kasahara Y, Kawamura F, Koga K, Koski P, Kuwana R, Imamura D, Ishimaru M, Ishikawa S, Ishio I, Le Coq D, Masson A, Mauël C, Meima R, Mellado RP, Moir A, Moriya S, Nagakawa E, Nanamiya H, Nakai S, Nygaard P, Ogura M, Ohanan T, O'Reilly M, O'Rourke M, Pragai Z, Pooley HM, Rapoport G, Rawlins JP, Rivas LA, Rivolta C, Sadaie A, Sadaie Y, Sarvas M, Sato T, Saxild HH, Scanlan E, Schumann W, Seegers JF, Sekiguchi J, Sekowska A, Séror SJ, Simon M, Stragier P, Studer R, Takamatsu H, Tanaka T, Takeuchi M, Thomaides HB, Vagner V, van Dijl JM, Watabe K, Wipat A, Yamamoto H, Yamamoto M, Yamamoto Y, Yamane K, Yata K, Yoshida K, Yoshikawa H, Zuber U, Ogasawara N.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4678-83. Epub 2003 Apr 7.

18.

The extracytoplasmic folding factor PrsA is required for protein secretion only in the presence of the cell wall in Bacillus subtilis.

Wahlström E, Vitikainen M, Kontinen VP, Sarvas M.

Microbiology. 2003 Mar;149(Pt 3):569-77.

PMID:
12634326
19.

Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes.

Sarén A, Pascolo S, Stevanovic S, Dumrese T, Puolakkainen M, Sarvas M, Rammensee HG, Vuola JM.

Infect Immun. 2002 Jul;70(7):3336-43.

20.

ClpXP protease regulates the signal peptide cleavage of secretory preproteins in Bacillus subtilis with a mechanism distinct from that of the Ecs ABC transporter.

Pummi T, Leskelä S, Wahlström E, Gerth U, Tjalsma H, Hecker M, Sarvas M, Kontinen VP.

J Bacteriol. 2002 Feb;184(4):1010-8.

21.

A novel two-component regulatory system in Bacillus subtilis for the survival of severe secretion stress.

Hyyryläinen HL, Bolhuis A, Darmon E, Muukkonen L, Koski P, Vitikainen M, Sarvas M, Prágai Z, Bron S, van Dijl JM, Kontinen VP.

Mol Microbiol. 2001 Sep;41(5):1159-72.

22.

Chlamydial antibodies in patients with previous acute anterior uveitis.

Huhtinen M, Puolakkainen M, Laasila K, Sarvas M, Karma A, Leirisalo-Repo M.

Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1816-9.

PMID:
11431447
23.

Proteome and transcriptome based analysis of Bacillus subtilis cells overproducing an insoluble heterologous protein.

Jürgen B, Hanschke R, Sarvas M, Hecker M, Schweder T.

Appl Microbiol Biotechnol. 2001 Apr;55(3):326-32.

PMID:
11341315
24.

Quantitation of the capacity of the secretion apparatus and requirement for PrsA in growth and secretion of alpha-amylase in Bacillus subtilis.

Vitikainen M, Pummi T, Airaksinen U, Wahlström E, Wu H, Sarvas M, Kontinen VP.

J Bacteriol. 2001 Mar;183(6):1881-90.

25.

Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte- derived macrophages.

Vehmaan-Kreula P, Puolakkainen M, Sarvas M, Welgus HG, Kovanen PT.

Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):E1-8.

PMID:
11145952
26.

Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2).

Penttilä T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Mäkelä PH, Puolakkainen M.

Vaccine. 2000 Dec 8;19(9-10):1256-65.

PMID:
11137265
27.

Picornavirus proteins share antigenic determinants with heat shock proteins 60/65.

Härkönen T, Puolakkainen M, Sarvas M, Airaksinen U, Hovi T, Roivainen M.

J Med Virol. 2000 Nov;62(3):383-91.

PMID:
11055249
28.

D-Alanine substitution of teichoic acids as a modulator of protein folding and stability at the cytoplasmic membrane/cell wall interface of Bacillus subtilis.

Hyyrylainen HL, Vitikainen M, Thwaite J, Wu H, Sarvas M, Harwood CR, Kontinen VP, Stephenson K.

J Biol Chem. 2000 Sep 1;275(35):26696-703.

29.

Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice.

Penttilä JM, Anttila M, Varkila K, Puolakkainen M, Sarvas M, Mäkelä PH, Rautonen N.

Immunology. 1999 Jul;97(3):490-6.

30.

Safe biotechnology 9: values in risk assessment for the environmental application of microorganisms. The Safety in Biotechnology Working Party of the European Federation of Biotechnology.

Doblhoff-Dier O, Bachmayer H, Bennett A, Brunius G, Bürki K, Cantley M, Collins C, Crooy P, Elmqvist A, Frontali-Botti C, Havenaar R, Haymerle H, Lelieveld H, Lex M, Mahler JL, Martinez L, Mosgaard C, Olsen L, Pazlarova J, Rudan F, Sarvas M, Stepankova H, Tzotzos G, Wagner K, Werner R.

Trends Biotechnol. 1999 Aug;17(8):307-11.

PMID:
10407401
31.

Handling of scientific dishonesty in the Nordic countries. National Committees on Scientific Dishonesty in the Nordic Countries.

Nylenna M, Andersen D, Dahlquist G, Sarvas M, Aakvaag A.

Lancet. 1999 Jul 3;354(9172):57-61.

PMID:
10406378
32.

Bacillus subtilis alpha-amylase: the rate limiting step of secretion is growth phase-independent.

Haddaoui E, Chambert R, Petit-Glatron MF, Lindy O, Sarvas M.

FEMS Microbiol Lett. 1999 Apr 1;173(1):127-31.

34.

Ecs, an ABC transporter of Bacillus subtilis: dual signal transduction functions affecting expression of secreted proteins as well as their secretion.

Leskelä S, Wahlström E, Hyyryläinen HL, Jacobs M, Palva A, Sarvas M, Kontinen VP.

Mol Microbiol. 1999 Jan;31(2):533-43.

35.

[Scientific fraud and misconduct--need for comprehensive terminology].

Riis P, Nylenna M, Dahlquist G, Sarvas M.

Nord Med. 1998 Dec;113(10):358-9. Danish. No abstract available.

PMID:
9925461
36.
37.

Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection.

Penttilä JM, Anttila M, Puolakkainen M, Laurila A, Varkila K, Sarvas M, Mäkelä PH, Rautonen N.

Infect Immun. 1998 Nov;66(11):5113-8.

38.

Expansion of a novel pulmonary CD3(-) CD4(+) CD8(+) cell population in mice during Chlamydia pneumoniae infection.

Penttilä JM, Pyhälä R, Sarvas M, Rautonen N.

Infect Immun. 1998 Jul;66(7):3290-4.

39.

Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100.

Idänpään-Heikkilä I, Wahlström E, Muttilainen S, Nurminen M, Käyhty H, Sarvas M, Mäkelä PH.

Vaccine. 1996 Jun;14(9):886-91.

PMID:
8843630
40.

[Meningococcal vaccine development].

Sarvas M.

Duodecim. 1996;112(9):806-12. Review. Finnish. No abstract available.

PMID:
10592968
42.

The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis.

Idänpään-Heikkilä I, Muttilainen S, Wahlström E, Saarinen L, Leinonen M, Sarvas M, Mäkelä PH.

Vaccine. 1995 Nov;13(16):1501-8.

PMID:
8578833
43.

The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes.

Muttilainen S, Idänpään-Heikkilä I, Wahlström E, Nurminen M, Mäkelä PH, Sarvas M.

Microb Pathog. 1995 Jun;18(6):423-36.

PMID:
8551945
44.

Heterologous production of the P1 porin of Neisseria meningitidis in bacillus subtilis: the effect of an N-terminal extension on the presentation of native-like epitopes.

Muttilainen S, Butcher SJ, Runeberg K, Nurminen M, Idänpään-Heikkilä I, Wahlström E, Sarvas M.

Microb Pathog. 1995 May;18(5):365-71.

PMID:
7476101
45.

Gene expression in recombinant Bacillus.

Sarvas M.

Bioprocess Technol. 1995;22:53-120. Review. No abstract available.

PMID:
7765537
46.

Biological activities of lipoteichoic acid and peptidoglycan-teichoic acid of Bacillus subtilis 168 (Marburg).

Himanen JP, Pyhälä L, Olander RM, Merimskaya O, Kuzina T, Lysyuk O, Pronin A, Sanin A, Helander IM, Sarvas M.

J Gen Microbiol. 1993 Nov;139(11):2659-65.

PMID:
8277249
47.

Immunological properties of recombinant porin of Haemophilus influenzae type b expressed in Bacillus subtilis.

Srikumar R, Dahan D, Gras MF, Saarinen L, Käyhty H, Sarvas M, Vogel L, Coulton JW.

Infect Immun. 1993 Aug;61(8):3334-41.

48.
49.
50.

Conformation of Escherichia coli outer membrane protein OmpA produced in Bacillus subtilis: influence of lipopolysaccharide.

Puohiniemi R, Muotiala A, Helander IM, Sarvas M.

FEMS Microbiol Lett. 1993 Jan 1;106(1):105-10.

PMID:
8440462

Supplemental Content

Loading ...
Support Center